INAVO120: Inavolisib with Palbociclib–Fulvestrant Doubles PFS in PIK3CA-Mutated Breast Cancer
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared a post by NEJM , on X:
“INAVO120 published in NEJM
In 1st-line treatment, inavolisib + palbociclib–fulvestrant improved PFS (15.0 vs. 7.3 months; HR 0.43, P<0.001) in PIK3CA-mutated, ER+/HER2- metastatic breast cancer vs. placebo Response rate: 58.4% vs. 25.0%.”
Quoting NEJM‘s post:
“INAVO120 trial: In PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib–fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib–fulvestrant.”
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
Authors: Nicholas C. Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J. Stout, Katherine E. Hutchinson, Jennifer L. Schutzman, Chunyan Song, and Komal L. Jhaveri.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023